基于决策树模型的强骨胶囊治疗原发性骨质疏松症的药物经济学研究  

Pharmacoeconomic study of qianggu capsule in the treatment of primary osteoporosis based on decision tree model

作　　者：崔鑫 李薇 魏戌[3] 陈明[4] 孙春全 石丰豪 谢雁鸣[1] 韩晟[2] CUI Xin;LI Wei;WEI Xu;CHEN Ming;SUN Chun-quan;SHI Feng-hao;XIE Yan-ming;HAN Sheng(Institute of Basic Research in Clinical Medicine,China Academy of Chinese Medical Sciences,Beijing 100700,China;International Research Center for Medicinal Administration,Peking University,Beijing 100191,China;Department of Academic,Wangjing Hospital,China Academy of Chinese Medical Sciences,Beijing 100102,China;Department of Bone Injury,Wangjing Hospital,China Academy of Chinese Medical Sciences,Beijing 100102,China;Department of Prevention and Treatment,Yuquan Hospital of Tsinghua University,Beijing 100049,China)

机构地区：[1]中国中医科学院中医临床基础医学研究所,北京100700 [2]北京大学医药管理国际研究中心,北京100191 [3]中国中医科学院望京医院学术处,北京100102 [4]中国中医科学院望京医院骨伤综合科,北京100102 [5]清华大学玉泉医院治未病科,北京100049

出　　处：《临床药物治疗杂志》2023年第4期34-39,共6页Clinical Medication Journal

基　　金：国家重点研发计划(2018YFC1707400)。

摘　　要：目的评价强骨胶囊治疗原发性骨质疏松症(POP)的经济性,以期为卫生医疗用药资源的合理配置提供参考依据。方法采用Treeage Pro软件对强骨胶囊(QC组)与骨松宝颗粒(GG组)治疗POP的成本-效果分析进行比较,成本参数源于米内网数据库和相关文献,同时根据一项临床研究得出的骨痛改善率评价2种治疗方案短期内的经济性,模型模拟的干预时间为3个月。通过单因素敏感性分析和概率敏感性分析对本研究结果的稳健性进行验证。结果基础分析结果显示,QC组的总成本低于GG组,同时所获得的健康收益高于GG组,临床效果更好。与GG组相比,QC组在POP患者的骨痛改善方面占有绝对优势,是绝对优势方案。敏感性分析结果验证了基础分析结果的稳健性,GG组的治疗成本和POP骨痛改善率对本研究结果有一定影响,概率敏感性分析中具有更高经济性概率的干预方案同基础分析结果一致。结论与骨松宝颗粒比较,POP患者选用强骨胶囊治疗在骨痛改善方面更具有经济性,且为绝对优势方案。Objective To evaluate the economy of qianggu capsule in the treatment of primary osteoporosis(POP),so as to provide reference for the rational allocation of medical medication resources.Methods In this study,Treeage Pro software was used to analyze the cost-effectiveness of qianggu capsule(QC group)vs gusongbao granules(GG group)on POP.The cost parameters were obtained from the Menet database and related literature.At the same time,the short-term economic efficiency of the two treatment was evaluated according to the improvement rate of bone pain obtained from a clinical study,and the intervention time simulated by the model was 3 months.The robustness of this study was verified by single factor sensitivity analysis and probabilistic sensitivity analysis.Results The results of basic analysis showed that the total cost of QC group was lower than that of GG group,and the health benefits of QC group was higher than that of GG group,and the clinical effect was better.Therefore,compared with GG group,QC group has an absolute advantage in the improvement of bone pain in patients with POP,and it was an absolutely superior.The results of sensitivity analysis verified the robustness of the results of the basic analysis.The treatment cost and the improvement effect of bone pain in GG group had a certain impact on the results of the study.The intervention with higher economic probability in probabilistic sensitivity analysis was consistent with the results of the basic analysis.Conclusion Compared with Gusongbao granules,qianggu capsule is more economical in the improvement of bone pain in POP patients,and it is the absolutely superior.

关 键 词：强骨胶囊 药物经济学评价 骨质疏松 成本-效果分析 骨松宝颗粒 

分 类 号：R956[医药卫生—药学]